PROMIS NEUROSCIENCES INC. Increase (Decrease) in Accrued Liabilities
PROMIS NEUROSCIENCES INC. (PMN) reported Increase (Decrease) in Accrued Liabilities of -$2.41 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-13
- PROMIS NEUROSCIENCES INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $558.80K, a 86.66% decline year-over-year.
- PROMIS NEUROSCIENCES INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$2.97M, a 225.07% decline year-over-year.
- PROMIS NEUROSCIENCES INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$131.15K.
- PROMIS NEUROSCIENCES INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $955.65K.
- PROMIS NEUROSCIENCES INC. increase (decrease) in accrued liabilities for fiscal 2025 was $7.39M.
- PROMIS NEUROSCIENCES INC. increase (decrease) in accrued liabilities for fiscal 2024 was -$1.03M.
- PROMIS NEUROSCIENCES INC. increase (decrease) in accrued liabilities for fiscal 2023 was -$1.83M, a 160.13% decline from fiscal 2022.
- PROMIS NEUROSCIENCES INC. increase (decrease) in accrued liabilities for fiscal 2022 was $3.05M, a 545.99% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $558.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.41M 10-Q · filed 2026-08-13 | -$2.54M derived: sum of 3 quarters · filed 2026-08-13 | -$1.59M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$2.97M 10-Q · filed 2026-05-12 | -$3.10M derived: sum of 2 quarters · filed 2026-05-12 | -$2.15M derived: sum of 3 quarters · filed 2026-05-12 | $2.04M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$131.15K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $824.51K derived: sum of 2 quarters · filed 2026-03-25 | $5.01M derived: sum of 3 quarters · filed 2026-08-13 | $7.39M 10-K · filed 2026-03-25 |
| 2025-09-30 | $955.65K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $5.14M derived: sum of 2 quarters · filed 2026-08-13 | $7.52M 10-Q · filed 2025-11-12 | $6.94M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $4.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $6.56M 10-Q · filed 2026-08-13 | $5.98M derived: sum of 3 quarters · filed 2026-08-13 | $5.89M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.38M 10-Q · filed 2026-05-12 | $1.80M derived: sum of 2 quarters · filed 2026-05-12 | $1.70M derived: sum of 3 quarters · filed 2026-05-12 | $1.61M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$578.89K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$675.83K derived: sum of 2 quarters · filed 2026-03-25 | -$761.36K derived: sum of 3 quarters · filed 2026-03-25 | -$1.03M 10-K · filed 2026-03-25 |
| 2024-09-30 | -$96.94K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$182.47K derived: sum of 2 quarters · filed 2025-11-12 | -$446.67K 10-Q · filed 2025-11-12 | $237.21K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$85.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$349.74K 10-Q · filed 2025-08-13 | $334.15K derived: sum of 3 quarters · filed 2025-08-13 | $513.30K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$264.20K 10-Q · filed 2025-05-12 | $419.68K derived: sum of 2 quarters · filed 2025-05-12 | $598.83K derived: sum of 3 quarters · filed 2025-05-12 | -$366.05K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $683.88K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $863.03K derived: sum of 2 quarters · filed 2025-03-31 | -$101.84K derived: sum of 3 quarters · filed 2025-03-31 | -$1.83M 10-K · filed 2025-03-31 |
| 2023-09-30 | $179.15K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$785.73K derived: sum of 2 quarters · filed 2024-11-14 | -$2.52M 10-Q · filed 2024-11-14 | -$353.44K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$964.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$2.69M 10-Q · filed 2024-08-08 | -$532.59K derived: sum of 3 quarters · filed 2024-08-08 | -$128.95K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$1.73M 10-Q · filed 2024-05-14 | $432.29K derived: sum of 2 quarters · filed 2024-05-14 | $835.93K derived: sum of 3 quarters · filed 2024-05-14 | $1.10M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $2.57M derived: sum of 2 quarters · filed 2024-04-01 | $2.83M derived: sum of 3 quarters · filed 2024-04-01 | $3.05M 10-K · filed 2024-04-01 |
| 2022-09-30 | $403.64K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $668.77K derived: sum of 2 quarters · filed 2023-11-14 | $883.93K 10-Q · filed 2023-11-14 | $1.13M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $265.13K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $480.29K 10-Q · filed 2023-08-14 | $727.81K derived: sum of 3 quarters · filed 2023-08-14 | $788.05K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $215.16K 10-Q · filed 2023-05-15 | $462.68K derived: sum of 2 quarters · filed 2023-05-15 | $522.92K derived: sum of 3 quarters · filed 2023-05-15 | |
| 2021-12-31 | $247.53K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $307.76K derived: sum of 2 quarters · filed 2023-03-08 | $471.46K 10-K · filed 2023-03-08 | |
| 2021-09-30 | $60.23K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $223.94K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $163.70K 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |